Vigneshkumar Dhandapani, Associate Vice President at Avalon Consulting, shared his views on Budget 2026 Expectations: Key Policy Levers for Indian Pharma, which was published in The Hindu BusinessLine and TICE.
He highlighted the need to raise healthcare spending to 2.5% of GDP in line with the National Health Policy, rationalise GST to address the inverted duty structure affecting MSMEs, expand the scope of the Pharma PLI to reduce API dependence on China, and revive the 200% weighted R&D deduction to strengthen innovation and long-term competitiveness in the Indian pharmaceutical industry.
